Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740672757> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2740672757 abstract "Cytotoxic T lymphocytes (CTLs) play critical roles in cancer-immune responses, and functional characterization of CTLs and their cancer-specific antigens will facilitate cancer immunotherapies. Immunogenic peptides, which can be derived from oncogenic proteins specifically expressed in cancer cells but not expressed in normal organs except testis (oncoantigens), or from peptides with somatic nonsynonymous mutations (neoantigens), are known as good targets for CTLs to eradicate cancer cells. In this study, we aimed to establish a method to efficiently identify oncoantigen/neoantigen-specific CTLs. Firstly, we screened candidate HLA-A2402-restricted oncoantigen/neoantigen peptides by in silico prediction of their binding affinity to MHC class I molecules. We conducted an in-vitro stimulation of CD8 lymphocytes carrying HLA-A24:02 allele by each peptide, and then confirmed clonal expansion of the peptide-specific CTLs by TCR repertoire sequencing analysis, interferon-γ enzyme-linked immunospot (ELISPOT) and/or peptide-HLA multimer assays. After identification of TCR alpha-beta pairs, we conducted retroviral transduction and prepared the TCR-engineered T cells to evaluate their cytotoxic activities against cancer cells. As oncoantigens, we isolated the CTLs for FOXM1 and UBE2T from healthy donors, and found these CTLs showed strong cytotoxicity against HLA-A2402-positive cancer cells expressing target proteins, but not against HLA-unmatched cancer cells. Similarly, the TCR-engineered T cells for FOXM1 and UBE2T showed killing effects for only HLA-A2402-positive cancer cells. Neoantigen-specific TCR-engineered CTLs also exhibited the mutated peptide-specific response, but did not cross-react to the nonmutated peptide. In addition, neoantigen-specific cytotoxicity was observed against HLA-A2402-positive cancer cells expressing the proteins with target somatic mutations. In conclusion, we developed the pipeline to screen possible onconatigens/neoantigens and establish antigen-specific TCR-engineered CTLs from peripheral blood lymphocytes. Our approach provides a promising strategy to develop personalized immunotherapies using onconatigen/neoantigen-reactive TCR-engineered T cells to treat cancer. Citation Format: Tatsuo Matsuda, Taigo Kato, Yuji Ikeda, Matthias Leisegang, Sachiko Yoshimura, Tetsuro Hikichi, Makiko Harada, Makda Zewde, Jae-Hyun Park, Hans Schreiber, Kazuma Kiyotani, Yusuke Nakamura. Eradication of cancer cells by T-cell receptor-engineered T cells targeting neoantigens/oncoantigens [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 625. doi:10.1158/1538-7445.AM2017-625" @default.
- W2740672757 created "2017-08-08" @default.
- W2740672757 creator A5000018452 @default.
- W2740672757 creator A5000207116 @default.
- W2740672757 creator A5004301579 @default.
- W2740672757 creator A5014080480 @default.
- W2740672757 creator A5014551715 @default.
- W2740672757 creator A5023434784 @default.
- W2740672757 creator A5037279585 @default.
- W2740672757 creator A5051015395 @default.
- W2740672757 creator A5062101990 @default.
- W2740672757 creator A5067683642 @default.
- W2740672757 creator A5076401952 @default.
- W2740672757 date "2017-07-01" @default.
- W2740672757 modified "2023-10-02" @default.
- W2740672757 title "Abstract 625: Eradication of cancer cells by T-cell receptor-engineered T cells targeting neoantigens/oncoantigens" @default.
- W2740672757 doi "https://doi.org/10.1158/1538-7445.am2017-625" @default.
- W2740672757 hasPublicationYear "2017" @default.
- W2740672757 type Work @default.
- W2740672757 sameAs 2740672757 @default.
- W2740672757 citedByCount "0" @default.
- W2740672757 crossrefType "proceedings-article" @default.
- W2740672757 hasAuthorship W2740672757A5000018452 @default.
- W2740672757 hasAuthorship W2740672757A5000207116 @default.
- W2740672757 hasAuthorship W2740672757A5004301579 @default.
- W2740672757 hasAuthorship W2740672757A5014080480 @default.
- W2740672757 hasAuthorship W2740672757A5014551715 @default.
- W2740672757 hasAuthorship W2740672757A5023434784 @default.
- W2740672757 hasAuthorship W2740672757A5037279585 @default.
- W2740672757 hasAuthorship W2740672757A5051015395 @default.
- W2740672757 hasAuthorship W2740672757A5062101990 @default.
- W2740672757 hasAuthorship W2740672757A5067683642 @default.
- W2740672757 hasAuthorship W2740672757A5076401952 @default.
- W2740672757 hasConcept C121608353 @default.
- W2740672757 hasConcept C147483822 @default.
- W2740672757 hasConcept C154317977 @default.
- W2740672757 hasConcept C167672396 @default.
- W2740672757 hasConcept C188280979 @default.
- W2740672757 hasConcept C19317047 @default.
- W2740672757 hasConcept C202751555 @default.
- W2740672757 hasConcept C203014093 @default.
- W2740672757 hasConcept C207936829 @default.
- W2740672757 hasConcept C2776090121 @default.
- W2740672757 hasConcept C2777701055 @default.
- W2740672757 hasConcept C2779053233 @default.
- W2740672757 hasConcept C2780674031 @default.
- W2740672757 hasConcept C502942594 @default.
- W2740672757 hasConcept C54355233 @default.
- W2740672757 hasConcept C86803240 @default.
- W2740672757 hasConcept C8840205 @default.
- W2740672757 hasConcept C8891405 @default.
- W2740672757 hasConcept C96232424 @default.
- W2740672757 hasConceptScore W2740672757C121608353 @default.
- W2740672757 hasConceptScore W2740672757C147483822 @default.
- W2740672757 hasConceptScore W2740672757C154317977 @default.
- W2740672757 hasConceptScore W2740672757C167672396 @default.
- W2740672757 hasConceptScore W2740672757C188280979 @default.
- W2740672757 hasConceptScore W2740672757C19317047 @default.
- W2740672757 hasConceptScore W2740672757C202751555 @default.
- W2740672757 hasConceptScore W2740672757C203014093 @default.
- W2740672757 hasConceptScore W2740672757C207936829 @default.
- W2740672757 hasConceptScore W2740672757C2776090121 @default.
- W2740672757 hasConceptScore W2740672757C2777701055 @default.
- W2740672757 hasConceptScore W2740672757C2779053233 @default.
- W2740672757 hasConceptScore W2740672757C2780674031 @default.
- W2740672757 hasConceptScore W2740672757C502942594 @default.
- W2740672757 hasConceptScore W2740672757C54355233 @default.
- W2740672757 hasConceptScore W2740672757C86803240 @default.
- W2740672757 hasConceptScore W2740672757C8840205 @default.
- W2740672757 hasConceptScore W2740672757C8891405 @default.
- W2740672757 hasConceptScore W2740672757C96232424 @default.
- W2740672757 hasLocation W27406727571 @default.
- W2740672757 hasOpenAccess W2740672757 @default.
- W2740672757 hasPrimaryLocation W27406727571 @default.
- W2740672757 hasRelatedWork W1540969335 @default.
- W2740672757 hasRelatedWork W1564484311 @default.
- W2740672757 hasRelatedWork W1966979298 @default.
- W2740672757 hasRelatedWork W2030164577 @default.
- W2740672757 hasRelatedWork W2031754253 @default.
- W2740672757 hasRelatedWork W2063021325 @default.
- W2740672757 hasRelatedWork W2149390157 @default.
- W2740672757 hasRelatedWork W2261427646 @default.
- W2740672757 hasRelatedWork W2531199937 @default.
- W2740672757 hasRelatedWork W2537448270 @default.
- W2740672757 hasRelatedWork W2565279123 @default.
- W2740672757 hasRelatedWork W2741062235 @default.
- W2740672757 hasRelatedWork W2785934310 @default.
- W2740672757 hasRelatedWork W2790014153 @default.
- W2740672757 hasRelatedWork W2885960162 @default.
- W2740672757 hasRelatedWork W2895264449 @default.
- W2740672757 hasRelatedWork W2914293490 @default.
- W2740672757 hasRelatedWork W2949948382 @default.
- W2740672757 hasRelatedWork W3012185908 @default.
- W2740672757 hasRelatedWork W58048110 @default.
- W2740672757 isParatext "false" @default.
- W2740672757 isRetracted "false" @default.
- W2740672757 magId "2740672757" @default.
- W2740672757 workType "article" @default.